USA flag logo/image

An Official Website of the United States Government

Search


Download to spreadsheetPrint
Displaying 76 – 100 of 8512 Awards
Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Current approaches to treat sudden sensorineural hearing loss (SSNHL) do not maintain inner ear drug concentrations within an appropriate therapeutic window for sufficient lengths of time to achieve therapeutic effect.A novel delivery system… more
Company: ORBIS BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …, and dangerous medicationerrors. At the foundation of the problem are palatability, accurate dosing, and age-appropriate dosage format challenges. Development of a user-friendly, inexpensive development platform for pediatric reformulation of existing adult drug… more
Company: ALTRAVAX, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … in 0.5-1.2 million deaths per year. Adults with chronic HBV infection acquired in the perinatal period develop hepatocellular carcinoma at a rate of about 5% per decade, approximately 100-fold higher than the rate among uninfected individuals. Antiviral drugs can… more
Company: PHOTOSWITCH BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: … the selective movement of charged molecules through cellular membranes. Many disease states, such as cystic fibrosis, muscular dystrophies, hypertension, and cardiac arrhythmias are caused by ion channel pathologies. Ion channels have been identified by the drug discovery… more
Company: NANOIMAGING SERVICES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: …opic of increasing concern in the biopharmaceutical industry, as these aggregates are believed to play an undesirable role resulting in adverse health effects to patients by inducing immunogenicity, altering therapeutic pharmacokinetics, or decreasing efficacy of the drug… more
Company: CRINETICS PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … of the HPG-axis and GnRH signaling, KISS1R is an attractive new mechanism for treating the cause of PCOS. KISS1R antagonists should dampen GnRH pulsatility and offer the first possibility of treating the disease at the hypothalamiclevel. To date there are no drug-like,… more
Company: KeraNetics, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: … Using this protocol, we will then examine the effect of KeraStat on delayed treatment and long-term outcomes in a porcine model of trauma/hemorrhage/shock. These data will be instrumental indeveloping a preclinical data package to be submitted to the US Food and Drug… more
Company: KeraNetics, LLC Agency/Program/Year/Phase: DOD / SBIR / 2012 / 1
Abstract: … may provide a platform on which regenerative strategies can be built. Keratins have intrinsic cell-binding properties that can be exploited to offer potential new solutions to wound healing and have been shown to be a viable platform for the controlled delivery of various drugs… more
Company: LongWave Photonics, LLC Agency/Program/Year/Phase: NSF / SBIR / 2012 / 1
Abstract: … such as structural foams, polymers and paints. Potential applications include the validation of the structural integrity of foams used in the aerospace industry; continuous monitoring of paint processes in the automotive industry; and the validation of pharmaceuticals… more
Company: REGENX, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …one of the leading causes of blindness. The prevalence of neovascular (wet) AMD in the United States is expected to increase to nearly 3 million by 2020. Existing treatments are effective in limiting the progression of the disease but are problematic in both cost of drug and… more
Company: STEMSYNERGY THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …urvival rate for patients with non-small-cell lung carcinoma (NSCLC) remain almost identical to20 years ago. Current therapies targeting the proliferative mechanisms of NSCLC cancers such as K-RAS and EGFR have been the focus of a large effort in the pharmaceutical industry and… more
Company: ACCELERATED MEDICAL DIAGNOSTICS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …, to establish protocols for the procedure and to gather preliminary clinical data. Breast cancer patients will receive a 14C-oxaliplatin microdose a few hours prior to normal biopsy. DNA will be isolated from white blood cells and left over tumor biopsy tissue. Drug-DNA… more
Company: CRYSTAL BIOSCIENCE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … development. PUBLIC HEALTH RELEVANCE: An estimated 33.4 million people worldwide are now living with HIV, and 2.7 million are newly infected every year, with a higher prevalence among women, as women are biologically more vulnerable to HIV than men. Anti-viral … more
Company: ISOTHERAPEUTICS GROUP, LLC Agency/Program/Year/Phase: DOE / SBIR / 2012 / 2
Abstract: … (MURR), typical irradiation parameters result in less than 2% of the 152Sm target material being converted into 153Sm. Since chemical methods cannot be used to perform isotopic separation, this means that & gt;98% of the resultant pharmaceutical molecules … more
Company: CARMOT THERAPEUTICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … challenging health problems of the 21st century. Global health care expenditures to treat diabetes and its complications are estimated to have been 376 billion in 2010, of which 198 billion was spent in the United States. Efficacious and convenient pharmaceutical… more
Company: RXI PHARMACEUTICALS CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …. Perhaps most significantly, this work has revealed that cancers can develop in response to mutations in tumor suppressor genes. Tumor suppressor mutations account for ~80% of all cancer mutations, but unlike activating mutations in oncogenes, cannot be targeted by drugs… more
Company: INSIGHT GENETICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: Constitutively activated forms of ALK caused by genetic aberrations have been shown to cause an expanding variety of human cancers. The FDA recently approved the Pfizer drug Xalkori (crizotinib) to treat patients with non-small cell lung cancers (NSCLC) that express ALK.… more
Company: INSIGHT GENETICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … development by several pharma and biotech firms. Similarly, ambiguous TKI treatments have also been used against non-NSCLC RET and DEPDC1 driven cancers in ongoing Phase Iand Phase II clinical trials with good efficacy. These trials should encourage numerous pharmaceutical… more
Company: SENSOPATH TECHNOLOGIES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: …. SensoPath Technologies will develop a detailed understanding of the dosimetry of the process, involving the interplay of targeting the receptor on the tumor surface, the delivery of pulsed near infrared (NIR) laser light in the range 800-840 nm, the method of drug… more
Company: Nanofiber Solutions Agency/Program/Year/Phase: NSF / STTR / 2012 / 2
Abstract: …FDA-approved sterilization procedures utilizing the Sterigenics gamma radiation facility, and 3) additional biological data providing both a head-to-head comparison of our products to those already on the market while also creating a market "pull" for the … more
Company: MBMR Agency/Program/Year/Phase: NSF / SBIR / 2012 / 2
Abstract: … cell lines, for the applicability of this method. The broader impact/commercial potential of this project, if successful, is a Fluorescent Imaging Kit that can be routinely used with such advanced techniques as high content screening, high throughput screening for … more
Company: Kapteyn-Murnane Laboratories Inc. Agency/Program/Year/Phase: NSF / SBIR / 2012 / 2
Abstract: … sciences. 2D IR spectroscopy provides structural and dynamical information that is difficult to obtain with other techniques, such as at inorganic/organic interfaces that are important in solar cell research or membrane proteins associated with pharmaceutical targets.… more
Company: SIMQUEST , LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Project Summary/Abstract Methamphetamine (meth), the fastest-growing illicit drug in the United States, is manufactured in makeshift laboratories using highly flammable and toxic ingredients. Most meth labs are discovered when fires,… more
Company: DNA MEDICINE INSTITUTE Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: … during chemotherapy and idiopathic thrombocytopenic purpura. During these situations, close and frequent monitoring of a patient's blood counts is a must to deliver the best care and treatment, whether it be blood transfusions, platelet transfusions, or drug… more
Company: 3-C INSTITUTE FOR SOCIAL DEVELOPMENT Agency/Program/Year/Phase: HHS / SBIR / 2012 / 2
Abstract: … used in the service of clinical or translational research in the social and behavioral sciences. Social and behavioral research plays a critical role in advancing the understanding and prevention of public health problems, both at the individual level (e.g., drug and alcohol… more
Displaying 76 – 100 of 8512 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.